David Hoskovec

Dr. David Hoskovec

orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2014 in Journal of Raman Spectroscopy
Verified
Journal Article
Closed access
PDF file
ASAlla Synytsya
Alla Synytsya
MJMiluse Judexova
Miluse Judexova
DHDavid Hoskovec
David Hoskovec
MMMichaela Miskovicova
Michaela Miskovicova
LPLubos Petruzelka
Lubos Petruzelka

16 January 2016 in Neoplasma
Verified
Journal Article
Closed access
LLLukas Lambert
Lukas Lambert
JHJ. Horejs
J. Horejs
ZKZdeněk Krška
Zdeněk Krška
DHDavid Hoskovec
David Hoskovec
LPL. Petruzelka
L. Petruzelka
JBJ. Briza
J. Briza
Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: general hospital cancer center experience

1 January 2017 in Archives of Medical Science
Verified
Journal Article
Open access
PDF file
DHDavid Hoskovec
David Hoskovec
JVJozef Varga
Jozef Varga
PDPetr Dytrych
Petr Dytrych
EKEllen Konecna
Ellen Konecna
JMJan Matek
Jan Matek
Introduction : Peritoneal tumor seeding is a common form of recurrence after gastric cancer surgery. The finding of free tumor cells and/or elevation of tumor markers in the peritoneal fluid could predict intraperitoneal tumor recurrence. The results of these examination can be used for...

14 December 2015 in Prague Medical Report
Verified
Journal Article
Open access
PDF file
ZKZdeněk Krška
Zdeněk Krška
JŠJan Šváb
Jan Šváb
DHDavid Hoskovec
David Hoskovec
JUJan Ulrych
Jan Ulrych
Pancreatic ductal adenocarcinoma (PDAC) represents permanent and ever rising issue worldwide. Five-year survival does not exceed 3 to 6%, i.e. the worst result among solid tumours. The article evaluates the current state of PDAC diagnostics and treatment specifying also development and trends. Percentage of non-resectable tumours due to locally advanced or metastatic condition varies 60–80%, mostly over 80%. Survival with non-resectable PDAC is 4 to 8 months (median 3.5). In contrast R0 resection shows the survival 18–27 months. Laboratory and imaging screening methods are not indicated on large scale. Risk factors are smoking, alcohol abuse, chronic pancreatitis, diabetes mellitus. Genetic background in most PDAC has not been detected yet. Some genes connected with high risk of PDAC (e.g. BRCA2, PALB2) have been identified as significant and highly penetrative, but link between PDAC and these genes can be seen only in 10–20%. This article surveys perspective oncogenes, tumour suppressor genes, microRNA. Albeit CT is still favoured over other imaging methods, involvement of NMR rises. Surgery prefers the “vessel first” approach, which proves to be justified especially in R0 resection. According to EBM immunotherapy same as radiotherapy are not significant in PDAC treatment. Chemotherapy shows limited importance in conversion treatment of locally advanced or borderline tumours or in case of metastatic spread. Unified procedures cannot be defined due to inhomogenous arrays. Surgical resection is the only chance for curative treatment of PDAC and depends mainly on timely indication for surgery and quality of multidisciplinary team in a high-volume centre.

1 June 2012 in Acta Cirurgica Brasileira
Verified
Journal Article
Open access
PDF file
DHDavid Hoskovec
David Hoskovec
JVJozef Varga
Jozef Varga
EKEllen Konečná
Ellen Konečná
FAFrantišek Antoš
František Antoš
PURPOSE: Tumor markers are substances found in blood and other biological fluids if tumor is present in the body. They can be produced by tumor itself or can be results of cancer - body relation. They may be used in the follow-up of cancer patients to identify tumor recurrence. Pre-treatment levels have prognostic tool and could signalize persistence of minimal residual disease despite radical surgery. METHODS: We operated on 52 patients with upper GI malignancy (32 with gastric cancer and 20 with pancreatic cancer). Blood samples were taken before surgery and peritoneal samples immediately after laparotomy before any manipulation with tumor. All samples were examined by standard biochemical technique and the level was compared with a stage of the disease. RESULTS: Patients suffering from gastric carcinoma of stage I and II had higher level of both markers in sera then in the peritoneal cavity, however most of them were within physiological range. Patients in stage III and IV had average marker levels in the peritoneal cavity higher than in sera. Number of positive findings was increasing according to the stage of the disease. The peritoneal levels of both markers varied extremely in higher stages. In patients suffering from pancreatic carcinoma the CEA levels both in sera and peritoneal cavity were parallel but peritoneal levels were slightly higher in stages III and IV. Ca 19 - 9 was more sensitive for pancreatic cancer. The percentage of positive findings was higher in sera but the level of Ca 19 - 9 was higher in the peritoneal cavity. The number of positive findings again correlated with the stage of the disease. CONCLUSIONS: Levels of tumor markers in sera could signalize inoperability of tumor (Ca 19 - 9 in cases of pancreatic carcinoma); peritoneal levels could predict R1 resection especially in gastric cancer patients and risk of early peritoneal recurrence of the disease. Difference between the levels in the peritoneum and sera may signalize the route of dissemination (hematogenous and intraperitoneal).

1 January 2015 in Videosurgery and Other Miniinvasive Techniques
Verified
Journal Article
Closed access
PKPavol Klobusicky
Pavol Klobusicky
DHDavid Hoskovec
David Hoskovec
Introduction : The role of fixation of the mesh is especially important in the endoscopic technique. The fixation of mesh through penetrating techniques using staples, clips or screws is associated with a significantly increased risk of developing a post-herniotomy pain syndrome. Aim: To...